Cargando…
Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
BACKGROUND: Neuromyelitis optica (NMO) is a chronic autoimmune disease of the central nervous system (CNS). The main immunological feature of the disease is the presence of autoantibodies to Aquaporin 4 (AQP4+), identified in about 82 % of cases. Currently, there are no reliable biomarkers for monit...
Autores principales: | Vaknin-Dembinsky, Adi, Charbit, Hanna, Brill, Livnat, Abramsky, Oded, Gur-Wahnon, Devorah, Ben-Dov, Iddo Z., Lavon, Iris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939003/ https://www.ncbi.nlm.nih.gov/pubmed/27393339 http://dx.doi.org/10.1186/s12974-016-0648-x |
Ejemplares similares
-
Sera of Neuromyelitis Optica Patients Increase BID-Mediated Apoptosis in Astrocytes
por: Zveik, Omri, et al.
Publicado: (2022) -
Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis
por: Lavon, Iris, et al.
Publicado: (2019) -
NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness
por: Mizrachi, Tehila, et al.
Publicado: (2018) -
Neuromyelitis optica (NMO) and autoimmune thyroiditis
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015) -
Autoimmune thyroiditis associated with neuromyelitis optica (NMO)
por: Sudulagunta, Sreenivasa Rao, et al.
Publicado: (2015)